2024
Pilot study of a novel, alternative subdermal scapular insertion site for the etonogestrel contraceptive implant
Clure C, Sheeder J, Lazorwitz A. Pilot study of a novel, alternative subdermal scapular insertion site for the etonogestrel contraceptive implant. Contraception 2024, 135: 110442. PMID: 38552822, DOI: 10.1016/j.contraception.2024.110442.Peer-Reviewed Original ResearchEtonogestrel contraceptive implantContraceptive implantsMedian body mass indexMedian pain scoreBody mass indexTime pointsBleeding side effectsEtonogestrel implantImplant placementReproductive-age femalesENG implantSite painPain scoresMedian ageInsertion siteEtonogestrelMass indexPilot studyPatient populationInferior edgeSide effectsPharmacokineticsImplantationWeeksSerum
2023
The effect of rifampin on serum etonogestrel concentrations and biomarkers of ovulation among contraceptive implant users: A pharmacokinetic and pharmacodynamic study
Lazorwitz A, Sheeder J, Teal S. The effect of rifampin on serum etonogestrel concentrations and biomarkers of ovulation among contraceptive implant users: A pharmacokinetic and pharmacodynamic study. Contraception 2023, 123: 110035. PMID: 36997081, PMCID: PMC10461170, DOI: 10.1016/j.contraception.2023.110035.Peer-Reviewed Original ResearchConceptsContraceptive implant usersSerum etonogestrel concentrationsStrong CYP3A inducersENG implant usersEtonogestrel concentrationsMedian ageImplant usersCYP3A inducersP4 concentrationsMedian body mass indexSerum E2 concentrationsBody mass indexSignificant decreaseParticipants' median ageSuppression of ovulationSerum P4 concentrationsEffect of rifampinDrug-drug interactionsLiquid chromatography-mass spectrometry assayOnly short exposuresWilcoxon signed-rank testBaseline E2Rifampin 600Rifampin exposureRifampin therapy
2022
Effect of Topiramate on Serum Etonogestrel Concentrations Among Contraceptive Implant Users
Lazorwitz A, Pena M, Sheeder J, Teal S. Effect of Topiramate on Serum Etonogestrel Concentrations Among Contraceptive Implant Users. Obstetrics And Gynecology 2022, 139: 579-587. PMID: 35594123, PMCID: PMC9140306, DOI: 10.1097/aog.0000000000004697.Peer-Reviewed Original ResearchConceptsSerum etonogestrel concentrationsContraceptive implant usersEtonogestrel concentrationsBody mass indexPg/Median ageImplant usersEnzyme-inducing antiepileptic drugsMedian body mass indexEffects of topiramateMean percent changeParticipants' median ageOvulatory suppressionTopiramate therapyMedian durationTopiramate useEtonogestrel implantsPharmacokinetic interactionsHealthy womenAntiepileptic drugsMass indexNoninferiority studyImplant useMass spectrometry assayPercent change
2020
An exploratory analysis on the influence of genetic variants on weight gain among etonogestrel contraceptive implant users
Lazorwitz A, Dindinger E, Harrison M, Aquilante C, Sheeder J, Teal S. An exploratory analysis on the influence of genetic variants on weight gain among etonogestrel contraceptive implant users. Contraception 2020, 102: 180-185. PMID: 32407811, PMCID: PMC7483263, DOI: 10.1016/j.contraception.2020.05.002.Peer-Reviewed Original ResearchConceptsBody mass indexEtonogestrel contraceptive implant usersEstrogen receptor 1Contraceptive implant usersContraceptive implant useWeight gainImplant useWeight changeImplant insertionEnrollment body mass indexMedian body mass indexGenetic variantsReproductive-aged womenMedian weight changeImplant usersExogenous steroid hormonesEstrogen receptor 1 geneReceptor 1 genePhysiologic plausibilityEtonogestrel implantsMetabolic syndromeMedical recordsContraceptive counselingRetrospective analysisIndividualized counseling
2019
Relationship between patient characteristics and serum etonogestrel concentrations in contraceptive implant users
Lazorwitz A, Aquilante C, Sheeder J, Guiahi M, Teal S. Relationship between patient characteristics and serum etonogestrel concentrations in contraceptive implant users. Contraception 2019, 100: 37-41. PMID: 30980827, PMCID: PMC6589369, DOI: 10.1016/j.contraception.2019.03.045.Peer-Reviewed Original ResearchConceptsSerum etonogestrel concentrationsContraceptive implant usersBody mass indexBlack/African American raceEtonogestrel concentrationsAfrican American raceMass indexPatient characteristicsImplant useEtonogestrel levelsImplant usersAmerican raceHispanic/Latina ethnicityMedian body mass indexSerum etonogestrel levelsEtonogestrel contraceptive implantSide effect profileReproductive-age womenCertain patient characteristicsIndividual patient characteristicsMajority of womenNon-significant increaseLatina ethnicityMedian ageSerum concentrations